February 27, 2018
SAN JOSE, Calif. – February 27, 2018 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced that it has created a joint venture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Hepalink), one of China’s leading pharmaceutical companies, to develop and gain regulatory approval for Aridis’ fully human monoclonal antibody (mAb) therapies for the greater China market.
January 24, 2018
B-TEMIA INC was announced as a finalist in the High Technology category for the FIDEIDES 2018 competition organized by the Chamber of Commerce of Quebec.
December 13, 2017
ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome Drew Pardoll, MD, Ph.D., Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins School of Medicine, as a new oncology advisor to Immunomic Therapeutics’ scientific advisory board.
December 05, 2017
November 22, 2017
ROCKVILLE, Md.–(BUSINESS WIRE)–Last week results from a study conducted by investigators in the laboratory of Duane Mitchell, M.D., Ph.D., director of the University of Florida Brain Tumor Immunotherapy Program and co-director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy, were presented at the 2017 Society for NeuroOncology (SNO) Annual Meeting.
September 12, 2017
Québec City, QC | September 12th, 2017 – B-TEMIA Inc., a Canadian biorobotic tech company and leader in the human augmentation market with its proprietary Dermoskeleton™ technology to aid mobility and Wistron Corporation, one of the world’s largest original design and manufacturers (ODMs) with revenues over CAD 25.5 billion, have signed an investment agreement whereby Wistron becomes a major shareholder in B-TEMIA.
August 02, 2017
SAN JOSE, Calif. – August 2, 2017 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody being developed to treat acute pneumonia caused by Gram-negative bacteria Pseudomonas aeruginosa. The randomized, double-blinded, placebo-controlled trial is ongoing in 14 countries worldwide.
May 18, 2017
Immunomic Therapeutics has entered an exclusive licensing agreement with Annias Immunotherapeutics for the rights to use Annia’s intellectual property regarding an immunotherapy based on antigens of cytomegalovirus (CMV). Both companies are developing new approaches for generating vaccines for cancer.
April 11, 2017
Québec City, QC | April 11, 2017 – B-TEMIA Inc., a leader in the human augmentation market, announces today that it has licensed its bionic augmentation technology Dermoskeleton™ to Lockheed Martin, who is eyeing a new generation of industrial and military exoskeletons.
March 07, 2017
A Canadian company has rolled out a wearable device to help people with mobility issues counteract the ravages of aging and disease.
December 20, 2016
TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas") and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., "Immunomic Therapeutics") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the drug candidate ASP0892 for the mitigation of severe hypersensitivity reactions due to peanut allergy. ASP0892 is a new DNA vaccine program based on the investigational LAMP-Vax platform. A Phase I clinical trial to evaluate the safety, tolerability and immune response of ASP0892 in adults allergic to peanuts has been initiated.
December 08, 2016
Calgary, Alberta, and Québec City, QC | December 8, 2016 – B-TEMIA Inc., a leader in the human augmentation market with its proprietary dermoskeletal technology, and Home Medical Solutions Inc., a provider of home medical equipment, today announce that they executed an agreement whereby Home Medical Solutions will be the primary distributor of the Keeogo™ powered walking assistance device in Alberta.
October 25, 2016
Québec City, QC | October 25, 2016 – B-TEMIA Inc., the developer and manufacturer of the Dermoskeleton™ mobility assistive technology announces that it has recently opened its new head office in St-Augustin, Québec City. The new facility will enable the Company to double its commercialization and manufacturing capacities.
October 04, 2016
ROCKVILLE, Md. & LINCOLN, Neb.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) and Nature Technology Corporation (NTC) announce today that they have entered into a new license agreement. The licensing of NTC’s RNA-OUT™ and HyperGro™ technology is part of ITI’s expansion into developing nucleic acid immunotherapies for cancer.
June 10, 2016
Québec City, QC | June 10, 2016 – B-TEMIA Inc. is proud to announce that the company received a $300,000 grant from the City of Québec aimed at advancing its DermokeletonTM technology as part of a close collaboration with the City’s Police and Fire Protection departments. This association will enable public security forces to try out the innovative robotic orthotic device developed by B-TEMIA.
May 16, 2016
ROCKVILLE, Md., May 16, 2016 /PRNewswire/ -- At the North Bethesda Marriott, Maryland's leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in the state on Thursday night's industry celebration.
April 13, 2016
April 13, 2016 – Québec, QC – One month after enabling a young female stroke survivor from Hamilton, ON, to climb the Grand Canyon, B-TEMIA, Inc. strikes again by providing an opportunity for an Asheville, NC, woman with an incomplete spinal cord injury to walk her first steps following paralysis, thanks to Keeogo™, a unique robotized walking device based on B-TEMIA’s proprietary Dermoskeleton™ technology.
March 29, 2016
HERSHEY, Pa. and ROCKVILLE, Md., March 29, 2016 /PRNewswire/ -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing next-generation immunotherapy platforms will be participating at the World Vaccine Congress taking March 29 to 31, 2016 in Washington DC.
November 23, 2015
Quebec, November 23, 2015 – B-TEMIA Inc., the market leader in human augmentation, today announced that it has initiated a multi-centre pivotal clinical trial, aimed at demonstrating the superior clinical benefits and safety for home use of its powered assistive Dermoskeleton™ technology, called Keeogo™, for patients suffering from reduced mobility due to their medical conditions. Led by Principal Investigator, Dr. Chris A. McGibbon, PhD, from the University of New Brunswick’s, Faculty of Kinesiology and Institute of Biomedical Engineering, the study is expected to generate the required data to support the submission of a 510(k) pre-market notification to the U.S. Food and Drug Administration in 2016, a prerequisite to start commercialization in the United States.
November 09, 2015
Canadian company B-Temia, Inc. and French company Sagem (Safran) today announced the signature of a technological and business development agreement concerning a new-generation of exoskeletons for industrial and military applications.
October 09, 2015
HERSHEY, Pa. and ROCKVILLE, Md., Oct. 9, 2015 /PRNewswire/ -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing next generation vaccines based on the LAMP-vax platform, today announced that it has entered into an exclusive worldwide licensing agreement with Astellas Pharma Inc. on LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans. Upon execution of the agreement, Immunomic Therapeutics will receive an upfront payment of $300 million and be entitled to receive 10 percent royalties based on net sales of the potential products for allergic diseases while retaining the rights to the LAMP-vax platform for other applications, including cancer immunotherapy.
May 13, 2015
HERSHEY, Pa. and ROCKVILLE, Md., May 13, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that the United States Department of Defense has awarded the company a $1.2M grant for the development of its ARA-LAMP-vax technology against peanut allergies.
March 31, 2015
HERSHEY, Pa. and ROCKVILLE, Md., March 31, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that the National Institutes of Health has awarded ITI's Small Business Innovation Research (SBIR) grant application titled, "Development of Nanoplasmid LAMP-based Peanut Allergy Immunotherapy." The work in this award will help the pre-clinical development of new and advanced therapeutic platforms for peanut allergies.
March 25, 2015
Hershey, PA, & Rockville, MD – March 25, 2015 – Immunomic Therapeutics, Inc., (“ITI”) a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it has concluded pre-IND discussions with the U.S. Food and Drug Administration regarding its proprietary ARALAMP-Vax vaccine currently under development for peanut allergies. The company received positive and helpful feedback, which it expects will be instrumental in designing its Phase 1 trials.
January 29, 2015
HERSHEY, Pa., Rockville, Md. and TOKYO, Jan. 29, 2015 /PRNewswire/ -- Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform,and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement forJapan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen. The companies expect to initiate a Phase 1 trial of JRC2-LAMP-vax in Japan as soon as it is ready.
1 / 1
SELECT MEDPRO NEWSLETTERS
1 / 1